Plant coumarins: Myths and realities

Alternative and Complementary Therapies

Volumn 15, Issue 1, 2009, Pages 24-30

  Yarnell, Eric ^a,b   Abascal, Kathy ^a  

^a Botanical Medicine Academy   (United States)

^b BASTYR UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61949273609     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/act.2009.15104     Document Type: Article

References (38)

1. Christensen TD, Maegaard M, Sørensen HT, et al. Self- versus conventional management of oral anticoagulant therapy: Effects on INR variability and coumarin dose in a randomized controlled trial. Am J Cardiovasc Drugs 2007;7:191-197.
2. McAlister V. Control of coagulation: A gift of Canadian agriculture. Clin Invest Med 2006;29:373-377.
3. Link PK. The discovery of dicoumarol and its sequels. Circulation 1959;19:97-107.
4. Edwards WC, Burrows GE, Tyr RJ. Toxic plants of Oklahoma: Clovers. Okla Vet Med Assoc 1984;36:30-32.
5. Kostering H, Bandura B, Merten HA, Wieding JU. The behavior of blood clotting and its inhibitors under long term treatment with 5,6-benzo-alpha- pyrone (coumarin): Double blind study [in German]. Arzneim Forsch 1985;35:1303-1306.
6. Koch E, Biber A. Treatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin. Phytomedicine 2007;14(suppl6):40-45.
7. Zou QZ, Bi RG, Li JM, et al. Effect of motherwort on blood hyperviscosity. Am J Chin Med 1989;17(1-2):65-70.
8. Lee CM, Jiang LM, Shang HS, et al. Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus. Br J Pharmacol 1991;103:1719-1724.
9. Segal R, Pilote L. Warfarin interaction with Matricaria chamomilla. CMAJ 2006;174:1281-1282.
10. Joss JD, LeBlond RF. Potentiation of warfarin anticoagulation associated with topical methyl salicylate. Ann Pharmacother 2000;34:729-733.
11. Chan TY. Drug interactions as a cause of overanticoagulation and bleedings in Chinese patients receiving warfarin. Int J Clin Pharmacol Ther 1998;36:403-405.
12. Chan TY. Potential dangers from topical preparations containing methyl salicylate. Hum Exp Toxicol 1996;15:747-50.
13. Desai UR. Coumarins. VCU School of Pharmacy. Last revised Jan 5, 2000. Online document at: www.people.vcu.edu/~urdesai/cou.htm. Accessed November 23, 2008.
14. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Nicolaides DN. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr Pharm Des 2004;10:3813-3833.
15. Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of a coumarin-troxerutin combination (SB-LOT) in patients with chronic venous insufficiency: A double blind placebo-controlled randomised study. Vasa 2002;31:185-190.
16. Badger C, Preston N, Seers K, Mortimer P. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev 2004; 2:CD003140.
17. Consoli A. Chronic venous insufficiency: An open trial of FLEBS Crema [in Italian]. Minerva Cardioangiol 2003;51:411-416.
18. Caraldi A, Gasbarro V, Viaggi R, et al. Effectiveness of the combination of alpha tocopherol, rutin, melilotus, and Centella asiatica in the treatment of patients with chronic venous insufficiency [in Italian]. Minerva Cardioangiol 2001;49:159-163.
19. Kulkarni MV, Kulkarni GM, Lin CH, Sun CM. Recent advances in coumarins and 1-azacoumarins as versatile biodynamic agents. Curr Med Chem 2006;13:2795-2818.
20. Musa MA, Cooperwood JS, Khan MO. A review of coumarin derivatives in pharmacotherapy of breast cancer. Curr Med Chem 2008;15:2664-2679.
21. Thornes RD, Daly L, Lynch G, et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol 1994;120(suppl):S32-S34.
22. Pedersen L, Rose C, Langvad E. Combined treatment of advanced malignant melanoma with coumarin and cimetidine: A phase II study. Cancer Immunol Immunother 1987;24:178-179.
23. Marshall ME, Butler K, Cantrell J, et al. Treatment of advanced malignant melanoma with coumarin and cimetidine: A pilot study. Cancer Chemother Pharmacol 1989;24:65-66.
24. Marshall ME, Butler K, Fried A. Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies. Mol Biother 1991;3:170-178.
25. Marshall ME, Mendelsohn L, Butler K, et al. Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: A pilot study. J Clin Oncol 1987;5:862-866.
26. Dexeus FH, Logothetis CJ, Sella A, et al. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol 1990;8:325-329.
27. Kokron O, Maca S, Gasser G, Schmidt PR. Cimetidine and coumarin therapy of renal cell carcinoma: A pilot study. Oncology 1991;48:102-106.
28. Hadidi H, Irshaid Y, Vagbo CB, et al. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6. Eur J Clin Pharmacol 1998; 54:437-441.
29. Rautio A, Kraul H, Kojo A, et al. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 1992;2:227-233.
30. Rietjens IM, Boersma MG, Zaleska M, Punt A. Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling. Toxicol In Vitro 2008;22:1890-1901.
31. Farinola N, Piller N. Pharmacogenomics: Its role in re-establishing coumarin as treatment for lymphedema. Lymphat Res Biol 2005;3:81-86.
32. Cox D, O'Kennedy R, Thornes RD. The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol 1989;8:501-506.
33. Schmeck-Lindenau HJ, Naser-Hijazi B, Becker EW, et al. Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. Int J Clin Pharmacol Ther 2003;41:193-199.
34. Loprinzi CL, Kugler JW, Sloan JA, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med 1999;340:346-350.
35. Adam BS, Pentz R, Siegers CP, et al. Troxerutin protects the isolated perfused rat liver from a possible lipid peroxidation by coumarin. Phytomedicine 2005;12(1-2):52-61.
36. Federal Institute for Risk Assessment. Frequently Asked Questions About Coumarin in Cinnamon and Other Foods. October 30, 2006. Online document at: www.bfr.bund.de/cm/279/frequently-asked-questions-about-coumarin-in-cinnamon- and-other-foods.pdf Accessed November 23, 2008.
37. Rychlik M. Quantification of free coumarin and its liberation from glucosylared precursors by stable isotope dilution assays based on liquid chromatography-tandem mass spectrometric detection. J Agric Food Chem 2008;56:796-801.
38. Pham AQ, Kourlas H, Pham DQ. Cinnamon supplementation in patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:595-599.